Shanta P. Boddapati, Ph.D. - Publications

Affiliations: 
2011 Chemical Engineering Arizona State University, Tempe, AZ, United States 
Area:
Biomedical Engineering, Molecular Biology, Neuroscience Biology

11/15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Yang G, Velgos SN, Boddapati SP, Sierks MR. Probing antibody-antigen interactions Microbiology Spectrum. 2: 1-13. DOI: 10.1128/microbiolspec. AID-0010-2013  0.534
2013 Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, Sierks MR. Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology Progress. 29: 463-71. PMID 23359572 DOI: 10.1002/Btpr.1698  0.637
2012 Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR. Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. Journal of Alzheimer's Disease : Jad. 28: 961-9. PMID 22156046 DOI: 10.3233/Jad-2011-111196  0.63
2012 Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR. Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of Aging. 33: 1320-8. PMID 21067847 DOI: 10.1016/J.Neurobiolaging.2010.09.020  0.677
2011 Boddapati S, Levites Y, Sierks MR. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. Journal of Molecular Biology. 405: 436-47. PMID 21073877 DOI: 10.1016/J.Jmb.2010.10.054  0.691
2010 Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. Bmc Neuroscience. 11: 57. PMID 20433710 DOI: 10.1186/1471-2202-11-57  0.558
2010 Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry. 49: 4501-8. PMID 20429609 DOI: 10.1021/Bi902030M  0.688
2010 Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnology Progress. 26: 1172-9. PMID 20306540 DOI: 10.1002/Btpr.396  0.687
2009 Wang M, Boddapati S, Sierks M. Response letter to comments on "Cyclodextrins promote protein aggregation posing risks for therapeutic applications". Biochemical and Biophysical Research Communications. 390: 1426-7. PMID 19852940 DOI: 10.1016/J.Bbrc.2009.10.073  0.579
2009 Wang MS, Boddapati S, Sierks MR. Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and Biophysical Research Communications. 386: 526-31. PMID 19540204 DOI: 10.1016/J.Bbrc.2009.06.077  0.684
2008 Boddapati SP, Sierks MR. P2-417: Beta-site specific ScFv's to decrease Abeta generation and toxicity in Alzheimer's disease Alzheimer's & Dementia. 4: T495-T496. DOI: 10.1016/J.Jalz.2008.05.1496  0.63
Low-probability matches (unlikely to be authored by this person)
2014 Yang G, Velgos SN, Boddapati SP, Sterks MR. Probing Antibody-Antigen Interactions. Microbiology Spectrum. 2: AID-0010-2013. PMID 26082105 DOI: 10.1128/microbiolspec.AID-0010-2013  0.226
2020 Boddapati S, Gilmore J, Boone K, Bushey J, Ross J, Gfeller B, McFee W, Rao R, Corrigan G, Chen A, Clarke H, Valliere-Douglass J, Bhargava S. Evidence for co-translational misincorporation of non-canonical amino acid hydroxyproline in recombinant antibodies produced in Chinese Hamster Ovary (CHO) cell lines. Plos One. 15: e0241250. PMID 33119652 DOI: 10.1371/journal.pone.0241250  0.162
2013 Iacovides DC, Johnson AB, Wang N, Boddapati S, Korkola J, Gray JW. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Molecular & Cellular Proteomics : McP. 12: 3210-20. PMID 23929892 DOI: 10.1074/mcp.M112.023119  0.117
2021 Garay JP, Smith R, Devlin K, Hollern DP, Liby T, Liu M, Boddapati S, Watson SS, Esch A, Zheng T, Thompson W, Babcock D, Kwon S, Chin K, Heiser L, et al. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Breast Cancer Research : Bcr. 23: 81. PMID 34344439 DOI: 10.1186/s13058-021-01457-0  0.041
Hide low-probability matches.